Fig. 7
WT1 inhibition attenuates tumor growth of BRAFV600E mutation PTC. A Western blot analysis indicated the stable inhibition efficiency of lentiviral WT1 shRNA treatment. B The image revealed the tumor volume in the control vector group and WT1 shRNA group. C The tumor volume of BRAFV600E PTC xenografts was measured every three days. D, E The tumor weight and tumor load of BRAFV600E PTC xenografts were determined when tumor-bearing mice were sacrificed. F HE staining indicated the pathological features of BRAFV600E PTC xenografts tissue with or wihout WT1 inhibition. G–L IHC analysis demonstrating that WT1 knockdown regulated the protein expression of Ki67, N-cadherin, ATG7, cleaved caspase 3, P-Akt and P-ERK in BRAFV600E PTC xenograft tissues. M, N Quantification of immunohistochemistry data of the protein expression of Ki67, N-cadherin, ATG7,cleaved caspase 3, P-Akt and P-ERK in BRAFV600E PTC xenograft tissues. (***P < 0.001, ****P < 0.0001)